jennifer brown, md, phd, on the addition of zanubrutinib to the nccn guidelines for cll
Published 3 years ago • 118 plays • Length 0:52
Download video MP4
Download video MP3
Similar videos
-
1:17
jennifer brown, md, phd, offers opinion on how zanubrutinib fits into the cll treatment landscape
-
2:06
jennifer brown, md, phd, provides perspective on the side-effect profiles of next-gen btk inhibitors
-
1:10
jennifer brown, md, phd, shares outcomes of arm c of the sequoia trial from ash 2020
-
1:05
jennifer brown, md, phd, considers the unmet needs in patients with cll or sll with del(17p)
-
0:48
jeffrey sharman, md, on the benefits of zanubrutinib as compared to other btk inhibitors
-
4:00
jennifer r. brown, md, phd: ibrutinib and atrial fibrillation risk in rcts
-
1:34
mazyar shadman, md, on the efficacy & tolerability of zanubrutinib in b-cell malignancies
-
0:59
dr. rule on the fda approval of zanubrutinib in mcl
-
0:42
dr. kristy a. brown
-
1:33
meet gynecologic oncologist jolyn taylor, m.d.
-
4:28
maternal-fetal medicine fellow: jennifer jacobson, md
-
2:24
anthony mato, md, msce, examines different treatment approaches to btk inhibitor intolerance
-
3:40
jennifer pennock, m.d., endocrinologist | genesis healthcare system
-
1:15
jane n. winter, md, explains how pd-1 and pd-l1 expression changes the way dlbcl is treated
-
3:00
regulation of pd-l1 in cutaneous lymphoma by mirnas
-
1:32
meet dr. jennifer flythe: nephrologist
-
15:09
novel targets and therapeutic perspectives in ibd: beyond anti-tnf
-
2:27
othman al-sawaf, md, regarding the standard of care for first-line treatment of newly diagnosed cll
-
0:20
how common is hypopharyngeal cancer? (jennifer bruening, md)
Clip.africa.com - Privacy-policy